Skip to main content
Top
Published in: Breast Cancer Research 3/2004

Open Access 01-06-2004 | Research article

Study design: Evaluating gene–environment interactions in the etiology of breast cancer – the WECARE study

Authors: Jonine L Bernstein, Bryan Langholz, Robert W Haile, Leslie Bernstein, Duncan C Thomas, Marilyn Stovall, Kathleen E Malone, Charles F Lynch, Jørgen H Olsen, Hoda Anton-Culver, Roy E Shore, John D Boice Jr, Gertrud S Berkowitz, Richard A Gatti, Susan L Teitelbaum, Susan A Smith, Barry S Rosenstein, Anne-Lise Børresen-Dale, Patrick Concannon, W Douglas Thompson

Published in: Breast Cancer Research | Issue 3/2004

Login to get access

Abstract

Introduction

Deficiencies in cellular responses to DNA damage can predispose to cancer. Ionizing radiation can cause cluster damage and double-strand breaks (DSBs) that pose problems for cellular repair processes. Three genes (ATM, BRCA1, and BRCA2) encode products that are essential for the normal cellular response to DSBs, but predispose to breast cancer when mutated.

Design

To examine the joint roles of radiation exposure and genetic susceptibility in the etiology of breast cancer, we designed a case-control study nested within five population-based cancer registries. We hypothesized that a woman carrying a mutant allele in one of these genes is more susceptible to radiation-induced breast cancer than is a non-carrier. In our study, 700 women with asynchronous bilateral breast cancer were individually matched to 1400 controls with unilateral breast cancer on date and age at diagnosis of the first breast cancer, race, and registry region, and counter-matched on radiation therapy. Each triplet comprised two women who received radiation therapy and one woman who did not. Radiation absorbed dose to the contralateral breast after initial treatment was estimated with a comprehensive dose reconstruction approach that included experimental measurements in anthropomorphic and water phantoms applying patient treatment parameters. Blood samples were collected from all participants for genetic analyses.

Conclusions

Our study design improves the potential for detecting gene–environment interactions for diseases when both gene mutations and the environmental exposures of interest are rare in the general population. This is particularly applicable to the study of bilateral breast cancer because both radiation dose and genetic susceptibility have important etiologic roles, possibly by interactive mechanisms. By using counter-matching, we optimized the informativeness of the collected dosimetry data by increasing the variability of radiation dose within the case–control sets and enhanced our ability to detect radiation–genotype interactions.
Appendix
Available only for authorised users
Literature
1.
go back to reference Gatti RA, Becker-Catania S, Chun HH, Sun X, Mitui M, Lai CH, Khanlou N, Babaei M, Cheng R, Clark C, Huo Y, Udar NC, Iyer RK: The pathogenesis of ataxia-telangiectasia. Learning from a Rosetta Stone. Clin Rev Allergy Immunol. 2001, 20: 87-108. 10.1385/CRIAI:20:1:87.CrossRefPubMed Gatti RA, Becker-Catania S, Chun HH, Sun X, Mitui M, Lai CH, Khanlou N, Babaei M, Cheng R, Clark C, Huo Y, Udar NC, Iyer RK: The pathogenesis of ataxia-telangiectasia. Learning from a Rosetta Stone. Clin Rev Allergy Immunol. 2001, 20: 87-108. 10.1385/CRIAI:20:1:87.CrossRefPubMed
2.
go back to reference Kastan MB, Lim DS, Kim ST, Yang D: ATM – a key determinant of multiple cellular responses to irradiation. Acta Oncol. 2001, 40: 686-688. 10.1080/02841860152619089.CrossRefPubMed Kastan MB, Lim DS, Kim ST, Yang D: ATM – a key determinant of multiple cellular responses to irradiation. Acta Oncol. 2001, 40: 686-688. 10.1080/02841860152619089.CrossRefPubMed
3.
go back to reference Cortez D, Wang Y, Qin J, Elledge SJ: Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science. 1999, 286: 1162-1166. 10.1126/science.286.5442.1162.CrossRefPubMed Cortez D, Wang Y, Qin J, Elledge SJ: Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science. 1999, 286: 1162-1166. 10.1126/science.286.5442.1162.CrossRefPubMed
4.
go back to reference Gatei M, Scott SP, Filippovitch I, Soronika N, Lavin MF, Weber B, Khanna KK: Role for ATM in DNA damage-induced phosphorylation of BRCA1. Cancer Res. 2000, 60: 3299-3304.PubMed Gatei M, Scott SP, Filippovitch I, Soronika N, Lavin MF, Weber B, Khanna KK: Role for ATM in DNA damage-induced phosphorylation of BRCA1. Cancer Res. 2000, 60: 3299-3304.PubMed
5.
go back to reference Ahn JY, Schwarz JK, Piwnica-Worms H, Canman CE: Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res. 2000, 60: 5934-5936.PubMed Ahn JY, Schwarz JK, Piwnica-Worms H, Canman CE: Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res. 2000, 60: 5934-5936.PubMed
6.
go back to reference Matsuoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K, Elledge SJ: Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci USA. 2000, 97: 10389-10394. 10.1073/pnas.190030497.CrossRefPubMedPubMedCentral Matsuoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K, Elledge SJ: Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci USA. 2000, 97: 10389-10394. 10.1073/pnas.190030497.CrossRefPubMedPubMedCentral
7.
go back to reference Melchionna R, Chen XB, Blasina A, McGowan CH: Threonine 68 is required for radiation-induced phosphorylation and activation of Cds1. Nat Cell Biol. 2000, 2: 762-765. 10.1038/35036406.CrossRefPubMed Melchionna R, Chen XB, Blasina A, McGowan CH: Threonine 68 is required for radiation-induced phosphorylation and activation of Cds1. Nat Cell Biol. 2000, 2: 762-765. 10.1038/35036406.CrossRefPubMed
8.
go back to reference Swift M, Morrell D, Massey RB, Chase CL: Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med. 1991, 325: 1831-1836.CrossRefPubMed Swift M, Morrell D, Massey RB, Chase CL: Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med. 1991, 325: 1831-1836.CrossRefPubMed
9.
go back to reference Swift M, Reitnauer PJ, Morrell D, Chase CL: Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med. 1987, 316: 1289-1294.CrossRefPubMed Swift M, Reitnauer PJ, Morrell D, Chase CL: Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med. 1987, 316: 1289-1294.CrossRefPubMed
10.
go back to reference Chenevix-Trench G, Spurdle AB, Gatei M, Kelly H, Marsh A, Chen X, Donn K, Cummings M, Nyholt D, Jenkins MA, Scott C, Pupo GM, Dork T, Bendix R, Kirk J, Tucker K, McCredie MR, Hopper JL, Sambrook J, Mann GJ, Khanna KK: Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst. 2002, 94: 205-215. 10.1093/jnci/94.3.205.CrossRefPubMed Chenevix-Trench G, Spurdle AB, Gatei M, Kelly H, Marsh A, Chen X, Donn K, Cummings M, Nyholt D, Jenkins MA, Scott C, Pupo GM, Dork T, Bendix R, Kirk J, Tucker K, McCredie MR, Hopper JL, Sambrook J, Mann GJ, Khanna KK: Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst. 2002, 94: 205-215. 10.1093/jnci/94.3.205.CrossRefPubMed
11.
go back to reference Dork T, Bendix R, Bremer M, Rades D, Klopper K, Nicke M, Skawran B, Hector A, Yamini P, Steinmann D, Weise S, Stuhrmann M, Karstens JH: Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients. Cancer Res. 2001, 61: 7608-7615.PubMed Dork T, Bendix R, Bremer M, Rades D, Klopper K, Nicke M, Skawran B, Hector A, Yamini P, Steinmann D, Weise S, Stuhrmann M, Karstens JH: Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients. Cancer Res. 2001, 61: 7608-7615.PubMed
12.
go back to reference Teraoka SN, Malone KE, Doody DR, Suter NM, Ostrander EA, Daling JR, Concannon P: Increased frequency of ATM mutations in breast carcinoma patients with early onset disease and positive family history. Cancer. 2001, 92: 479-487. 10.1002/1097-0142(20010801)92:3<479::AID-CNCR1346>3.0.CO;2-G.CrossRefPubMed Teraoka SN, Malone KE, Doody DR, Suter NM, Ostrander EA, Daling JR, Concannon P: Increased frequency of ATM mutations in breast carcinoma patients with early onset disease and positive family history. Cancer. 2001, 92: 479-487. 10.1002/1097-0142(20010801)92:3<479::AID-CNCR1346>3.0.CO;2-G.CrossRefPubMed
13.
go back to reference Spring K, Ahangari F, Scott SP, Waring P, Purdie DM, Chen PC, Hourigan K, Ramsay J, McKinnon PJ, Swift M, Lavin MF: Mice heterozygous for mutation in Atm, the gene involved in ataxia-telangiectasia, have heightened susceptibility to cancer. Nat Genet. 2002, 32: 185-190. 10.1038/ng958.CrossRefPubMed Spring K, Ahangari F, Scott SP, Waring P, Purdie DM, Chen PC, Hourigan K, Ramsay J, McKinnon PJ, Swift M, Lavin MF: Mice heterozygous for mutation in Atm, the gene involved in ataxia-telangiectasia, have heightened susceptibility to cancer. Nat Genet. 2002, 32: 185-190. 10.1038/ng958.CrossRefPubMed
14.
go back to reference Chakraborty R, Little MP, Sankaranarayanan K: Cancer predisposition, radiosensitivity and the risk of radiation-induced cancers. IV. Prediction of risks in relatives of cancer-predisposed individuals. Radiat Res. 1998, 149: 493-507.CrossRefPubMed Chakraborty R, Little MP, Sankaranarayanan K: Cancer predisposition, radiosensitivity and the risk of radiation-induced cancers. IV. Prediction of risks in relatives of cancer-predisposed individuals. Radiat Res. 1998, 149: 493-507.CrossRefPubMed
15.
go back to reference Hall EJ: Radiation, the two-edged sword: cancer risks at high and low doses. Cancer J. 2000, 6: 343-350.PubMed Hall EJ: Radiation, the two-edged sword: cancer risks at high and low doses. Cancer J. 2000, 6: 343-350.PubMed
16.
go back to reference Horn PL, Thompson WD, Schwartz SM: Factors associated with the risk of second primary breast cancer: an analysis of data from the Connecticut Tumor Registry. J Chronic Dis. 1987, 40: 1003-1011. 10.1016/0021-9681(87)90114-7.CrossRefPubMed Horn PL, Thompson WD, Schwartz SM: Factors associated with the risk of second primary breast cancer: an analysis of data from the Connecticut Tumor Registry. J Chronic Dis. 1987, 40: 1003-1011. 10.1016/0021-9681(87)90114-7.CrossRefPubMed
17.
go back to reference John EM, Kelsey JL: Radiation and other environmental exposures and breast cancer. Epidemiol Rev. 1993, 15: 157-162.CrossRefPubMed John EM, Kelsey JL: Radiation and other environmental exposures and breast cancer. Epidemiol Rev. 1993, 15: 157-162.CrossRefPubMed
18.
go back to reference Shore RE, Hildreth N, Woodard E, Dvoretsky P, Hempelmann L, Pasternack B: Breast cancer among women given X-ray therapy for acute postpartum mastitis. J Natl Cancer Inst. 1986, 77: 689-696.PubMed Shore RE, Hildreth N, Woodard E, Dvoretsky P, Hempelmann L, Pasternack B: Breast cancer among women given X-ray therapy for acute postpartum mastitis. J Natl Cancer Inst. 1986, 77: 689-696.PubMed
19.
go back to reference Howe GR, McLaughlin J: Breast cancer mortality between 1950 and 1987 after exposure to fractionated moderate-dose-rate ionizing radiation in the Canadian fluoroscopy cohort study and a comparison with breast cancer mortality in the atomic bomb survivors study. Radiat Res. 1996, 145: 694-707.CrossRefPubMed Howe GR, McLaughlin J: Breast cancer mortality between 1950 and 1987 after exposure to fractionated moderate-dose-rate ionizing radiation in the Canadian fluoroscopy cohort study and a comparison with breast cancer mortality in the atomic bomb survivors study. Radiat Res. 1996, 145: 694-707.CrossRefPubMed
20.
go back to reference Little MP, Boice JD: Comparison of breast cancer incidence in the Massachusetts tuberculosis fluoroscopy cohort and in the Japanese atomic bomb survivors. Radiat Res. 1999, 151: 218-224.CrossRefPubMed Little MP, Boice JD: Comparison of breast cancer incidence in the Massachusetts tuberculosis fluoroscopy cohort and in the Japanese atomic bomb survivors. Radiat Res. 1999, 151: 218-224.CrossRefPubMed
21.
go back to reference Preston DL, Mattsson A, Holmberg E, Shore R, Hildreth NG, Boice JD: Radiation effects on breast cancer risk: a pooled analysis of eight cohorts. Radiat Res. 2002, 158: 220-235.CrossRefPubMed Preston DL, Mattsson A, Holmberg E, Shore R, Hildreth NG, Boice JD: Radiation effects on breast cancer risk: a pooled analysis of eight cohorts. Radiat Res. 2002, 158: 220-235.CrossRefPubMed
22.
go back to reference Boice JD, Preston D, Davis FG, Monson RR: Frequent chest X-ray fluoroscopy and breast cancer incidence among tuberculosis patients in Massachusetts. Radiat Res. 1991, 125: 214-222.CrossRefPubMed Boice JD, Preston D, Davis FG, Monson RR: Frequent chest X-ray fluoroscopy and breast cancer incidence among tuberculosis patients in Massachusetts. Radiat Res. 1991, 125: 214-222.CrossRefPubMed
23.
go back to reference Travis LB, Hill DA, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Wiklund T, Lynch CF, Van't Veer MB, Glimelius I, Storm H, Pukkala E, Stovall M, Curtis R, Boice JD, Gilbert E: Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA. 2003, 290: 465-475. 10.1001/jama.290.4.465.CrossRefPubMed Travis LB, Hill DA, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Wiklund T, Lynch CF, Van't Veer MB, Glimelius I, Storm H, Pukkala E, Stovall M, Curtis R, Boice JD, Gilbert E: Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA. 2003, 290: 465-475. 10.1001/jama.290.4.465.CrossRefPubMed
25.
go back to reference Tercilla O, Krasin F, Lawn-Tsao L: Comparison of contralateral breast doses from 1/2 beam block and isocentric treatment techniques for patients treated with primary breast irradiation with 60CO. Int J Radiat Oncol Biol Phys. 1989, 17: 205-210.CrossRefPubMed Tercilla O, Krasin F, Lawn-Tsao L: Comparison of contralateral breast doses from 1/2 beam block and isocentric treatment techniques for patients treated with primary breast irradiation with 60CO. Int J Radiat Oncol Biol Phys. 1989, 17: 205-210.CrossRefPubMed
26.
go back to reference Fraass BA, Roberson PL, Lichter AS: Dose to the contralateral breast due to primary breast irradiation. Int J Radiat Oncol Biol Phys. 1985, 11: 485-497.CrossRefPubMed Fraass BA, Roberson PL, Lichter AS: Dose to the contralateral breast due to primary breast irradiation. Int J Radiat Oncol Biol Phys. 1985, 11: 485-497.CrossRefPubMed
27.
go back to reference Boice JD, Harvey EB, Blettner M, Stovall M, Flannery JT: Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med. 1992, 326: 781-785.CrossRefPubMed Boice JD, Harvey EB, Blettner M, Stovall M, Flannery JT: Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med. 1992, 326: 781-785.CrossRefPubMed
29.
30.
go back to reference Begg CB, Berwick M: A note on the estimation of relative risks of rare genetic susceptibility markers. Cancer Epidemiol Biomarkers Prev. 1997, 6: 99-103.PubMed Begg CB, Berwick M: A note on the estimation of relative risks of rare genetic susceptibility markers. Cancer Epidemiol Biomarkers Prev. 1997, 6: 99-103.PubMed
31.
go back to reference Malkin D, Jolly KW, Barbier N, Look AT, Friend SH, Gebhardt MC, Andersen TI, Borresen AL, Li FP, Garber J: Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med. 1992, 326: 1309-1315.CrossRefPubMed Malkin D, Jolly KW, Barbier N, Look AT, Friend SH, Gebhardt MC, Andersen TI, Borresen AL, Li FP, Garber J: Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med. 1992, 326: 1309-1315.CrossRefPubMed
32.
go back to reference Meadows AT, Strong LC, Li FP, D'Angio GJ, Schweisguth O, Freeman AI, Jenkin RD, Morris-Jones P, Nesbit ME: Bone sarcoma as a second malignant neoplasm in children: influence of radiation and genetic predisposition for the Late Effects Study Group. Cancer. 1980, 46: 2603-2606.CrossRefPubMed Meadows AT, Strong LC, Li FP, D'Angio GJ, Schweisguth O, Freeman AI, Jenkin RD, Morris-Jones P, Nesbit ME: Bone sarcoma as a second malignant neoplasm in children: influence of radiation and genetic predisposition for the Late Effects Study Group. Cancer. 1980, 46: 2603-2606.CrossRefPubMed
33.
go back to reference Rayner CR, Towers JF, Wilson JS: What is Gorlin's syndrome? The diagnosis and management of the basal cell naevus syndrome, based on a study of thirty-seven patients. Br J Plast Surg. 1977, 30: 62-67.CrossRefPubMed Rayner CR, Towers JF, Wilson JS: What is Gorlin's syndrome? The diagnosis and management of the basal cell naevus syndrome, based on a study of thirty-seven patients. Br J Plast Surg. 1977, 30: 62-67.CrossRefPubMed
35.
go back to reference Wong FL, Boice JD, Abramson DH, Tarone RE, Kleinerman RA, Stovall M, Goldman MB, Seddon JM, Tarbell N, Fraumeni JF, Li FP: Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA. 1997, 278: 1262-1267. 10.1001/jama.278.15.1262.CrossRefPubMed Wong FL, Boice JD, Abramson DH, Tarone RE, Kleinerman RA, Stovall M, Goldman MB, Seddon JM, Tarbell N, Fraumeni JF, Li FP: Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA. 1997, 278: 1262-1267. 10.1001/jama.278.15.1262.CrossRefPubMed
36.
go back to reference Robins JM, Gail MH, Lubin JH: More on 'Biased selection of controls for case-control analyses of cohort studies'. Biometrics. 1986, 42: 293-299.CrossRefPubMed Robins JM, Gail MH, Lubin JH: More on 'Biased selection of controls for case-control analyses of cohort studies'. Biometrics. 1986, 42: 293-299.CrossRefPubMed
37.
go back to reference Langholz B, Goldstein L: Risk set sampling in epidemiologic cohort studies. Statist Science. 1996, 11: 35-53. 10.1214/ss/1032209663.CrossRef Langholz B, Goldstein L: Risk set sampling in epidemiologic cohort studies. Statist Science. 1996, 11: 35-53. 10.1214/ss/1032209663.CrossRef
38.
go back to reference Langholz B, Goldstein L: Fitting logistic models using conditional logistic likelihood when there are large strata. Comput Sci Statist. 1997, 29: 551-555. Langholz B, Goldstein L: Fitting logistic models using conditional logistic likelihood when there are large strata. Comput Sci Statist. 1997, 29: 551-555.
40.
go back to reference Bernstein JL, Teraoka S, Haile RW, Borresen-Dale AL, Rosenstein BS, Gatti RA, Diep AT, Jansen L, Atencio DP, Olsen JH, Bernstein L, Teitelbaum SL, Thompson WD, Concannon P: Designing and implementing quality control for multi-center screening of mutations in the ATM gene among women with breast cancer. Hum Mutat. 2003, 21: 542-550. 10.1002/humu.10206.CrossRefPubMed Bernstein JL, Teraoka S, Haile RW, Borresen-Dale AL, Rosenstein BS, Gatti RA, Diep AT, Jansen L, Atencio DP, Olsen JH, Bernstein L, Teitelbaum SL, Thompson WD, Concannon P: Designing and implementing quality control for multi-center screening of mutations in the ATM gene among women with breast cancer. Hum Mutat. 2003, 21: 542-550. 10.1002/humu.10206.CrossRefPubMed
41.
go back to reference Andrieu N, Goldstein AM, Thomas DC, Langholz B: Counter-matching in studies of gene–environment interaction: efficiency and feasibility. Am J Epidemiol. 2001, 153: 265-274. 10.1093/aje/153.3.265.CrossRefPubMed Andrieu N, Goldstein AM, Thomas DC, Langholz B: Counter-matching in studies of gene–environment interaction: efficiency and feasibility. Am J Epidemiol. 2001, 153: 265-274. 10.1093/aje/153.3.265.CrossRefPubMed
42.
go back to reference Cologne J, Langholz B: Selecting controls for assessing interaction in nested case-control studies. J Epidemiol. 2003, 13: 193-202.CrossRefPubMed Cologne J, Langholz B: Selecting controls for assessing interaction in nested case-control studies. J Epidemiol. 2003, 13: 193-202.CrossRefPubMed
44.
go back to reference Malin JL, Kahn KL, Adams J, Kwan L, Laouri M, Ganz PA: Validity of cancer registry data for measuring the quality of breast cancer care. J Natl Cancer Inst. 2002, 94: 835-844. 10.1093/jnci/94.11.835.CrossRefPubMed Malin JL, Kahn KL, Adams J, Kwan L, Laouri M, Ganz PA: Validity of cancer registry data for measuring the quality of breast cancer care. J Natl Cancer Inst. 2002, 94: 835-844. 10.1093/jnci/94.11.835.CrossRefPubMed
45.
go back to reference Siemiatycki J, Thomas DC: Biological models and statistical interactions: an example from multistage carcinogenesis. Int J Epidemiol. 1981, 10: 383-387.CrossRefPubMed Siemiatycki J, Thomas DC: Biological models and statistical interactions: an example from multistage carcinogenesis. Int J Epidemiol. 1981, 10: 383-387.CrossRefPubMed
46.
go back to reference Clayton D, McKeigue PM: Epidemiological methods for studying genes and environmental factors in complex diseases. Lancet. 2001, 358: 1356-1360. 10.1016/S0140-6736(01)06418-2.CrossRefPubMed Clayton D, McKeigue PM: Epidemiological methods for studying genes and environmental factors in complex diseases. Lancet. 2001, 358: 1356-1360. 10.1016/S0140-6736(01)06418-2.CrossRefPubMed
47.
go back to reference Rothman N, Wacholder S, Caporaso NE, Garcia-Closas M, Buetow K, Fraumeni JF: The use of common genetic polymorphisms to enhance the epidemiologic study of environmental carcinogens. Biochim Biophys Acta. 2001, 1471: C1-C10. 10.1016/S0304-419X(00)00021-4.PubMed Rothman N, Wacholder S, Caporaso NE, Garcia-Closas M, Buetow K, Fraumeni JF: The use of common genetic polymorphisms to enhance the epidemiologic study of environmental carcinogens. Biochim Biophys Acta. 2001, 1471: C1-C10. 10.1016/S0304-419X(00)00021-4.PubMed
48.
go back to reference Brennan P: Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it?. Carcinogenesis. 2002, 23: 381-387. 10.1093/carcin/23.3.381.CrossRefPubMed Brennan P: Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it?. Carcinogenesis. 2002, 23: 381-387. 10.1093/carcin/23.3.381.CrossRefPubMed
49.
go back to reference Thomas DC: Temporal effects and interactions in cancer: implications of carcinogenic models. In Environmental Epidemiology: Risk Assessment. Edited by: Prentice RL, Whittemore AS. 1982, Philadelphia: Society for Industrial and Applied Mathematics, 107-121. Thomas DC: Temporal effects and interactions in cancer: implications of carcinogenic models. In Environmental Epidemiology: Risk Assessment. Edited by: Prentice RL, Whittemore AS. 1982, Philadelphia: Society for Industrial and Applied Mathematics, 107-121.
50.
go back to reference Langholz B, Borgan O: Counter-matching: a stratified nested case-control sampling method. Biometrika. 1995, 82: 69-79.CrossRef Langholz B, Borgan O: Counter-matching: a stratified nested case-control sampling method. Biometrika. 1995, 82: 69-79.CrossRef
51.
go back to reference Huberman M, Langholz B: Application of the missing-indicator method in matched case-control studies with incomplete data. Am J Epidemiol. 1999, 150: 1340-1345.CrossRefPubMed Huberman M, Langholz B: Application of the missing-indicator method in matched case-control studies with incomplete data. Am J Epidemiol. 1999, 150: 1340-1345.CrossRefPubMed
Metadata
Title
Study design: Evaluating gene–environment interactions in the etiology of breast cancer – the WECARE study
Authors
Jonine L Bernstein
Bryan Langholz
Robert W Haile
Leslie Bernstein
Duncan C Thomas
Marilyn Stovall
Kathleen E Malone
Charles F Lynch
Jørgen H Olsen
Hoda Anton-Culver
Roy E Shore
John D Boice Jr
Gertrud S Berkowitz
Richard A Gatti
Susan L Teitelbaum
Susan A Smith
Barry S Rosenstein
Anne-Lise Børresen-Dale
Patrick Concannon
W Douglas Thompson
Publication date
01-06-2004
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 3/2004
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr771

Other articles of this Issue 3/2004

Breast Cancer Research 3/2004 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine